Carna Biosciences, Inc.
4572カルナバイオサイエンス株式会社
Latest half-year results
First half · fiscal year to 2026-12 · filed 2026-08-07For the first half of the fiscal year to 2026-12: Revenue ¥0.4 billion (+59.8% YoY), Ordinary income ¥-1 billion, Net income ¥-1 billion.
| This period | Year on year | |
|---|---|---|
| Revenue | ¥401m | +59.8% |
| Ordinary profit | −¥1.0bn | — |
| Net profit to owners | −¥1.0bn | — |
From the securities report on EDINET, which states no forecast. History via /v1/companies/4572/earnings-releases.
Financials
Japan GAAP · consolidated · fiscal year to 2025-12-31- Revenue
- ¥579m
- Net income
- −¥2.2bn
- ROE
- —
- Equity ratio
- 25.1%
- Dividend / share
- —
- Employees
- 61
| Fiscal year | Revenue | Net income | Total assets | Net assets | ROE | EPS | Operating CF |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | ¥579m | −¥2,171m | ¥1,230m | ¥309m | — | ¥-113.62 | −¥2,159m |
| 2024-12-31 | ¥636m | −¥2,179m | ¥2,772m | ¥2,475m | — | ¥-121.64 | −¥1,375m |
| 2023-12-31 | ¥1,626m | −¥1,153m | ¥4,350m | ¥3,878m | — | ¥-68.62 | −¥1,677m |
| 2022-12-31 | ¥1,387m | −¥1,350m | ¥4,266m | ¥3,642m | — | ¥-99.1 | −¥708m |
| 2021-12-31 | ¥2,018m | −¥534m | ¥5,433m | ¥4,316m | — | ¥-42.1 | −¥1,537m |
Indicators
Computed by us from filings · fiscal year to 2025-12-31| Metric | Value | Percentile among listed companies |
|---|---|---|
| ROE, % | — | — |
| Ordinary margin | -3.7041 | 0.6 |
| Equity ratio, % | 25.1 | 10.2 |
| Revenue growth | -0.0899 | 7.3 |
| Net income growth | 0.0033 | 35.9 |
| Operating cash flow / assets | -1.7561 | 0.1 |
Results wording balance: +0.09. Proprietary text method; it describes the wording only and does not interpret context.
Interest example: if all ¥690m of reported debt repriced by 50 basis points, a year's interest would rise by ¥3m. Our arithmetic only, not a forecast: fixed-rate debt and hedges are ignored.
Via /v1/companies/4572/indicators. Descriptive figures, not a rating and not investment advice.
From other filings
As the company states themSegments, votes and tender offers
Stated in EDINET filings/v1/companies/4572/segments/v1/companies/4572/votingOwnership changes
All companies →- 2026-11-06
individual filer reduced holdings in Carna Biosciences, Inc. (4572) to 24.57% from 25.65%.
- 2026-10-20
individual filer raised holdings in Carna Biosciences, Inc. (4572) to 13.68% from 6.66%.
- 2026-10-20
Holdings of individual filer in Carna Biosciences, Inc. (4572) moved above 10% (6.66% -> 13.68%).
- 2026-10-19
individual filer reduced holdings in Carna Biosciences, Inc. (4572) to 25.65% from 27.24%.
- 2026-10-14
individual filer raised holdings in Carna Biosciences, Inc. (4572) to 6.66% from 5.14%.
- 2026-10-09
individual filer reduced holdings in Carna Biosciences, Inc. (4572) to 27.24% from 28.34%.
- 2026-07-29
individual filer reduced holdings in Carna Biosciences, Inc. (4572) to 28.34% from 30.21%.
- 2026-06-02
individual filer reduced holdings in Carna Biosciences, Inc. (4572) to 30.21% from 31.50%.
- 2026-05-20
individual filer reduced holdings in Carna Biosciences, Inc. (4572) to 31.50% from 33.20%.
- 2026-05-20
individual filer filed a correction to a 5% report on Carna Biosciences, Inc. (4572).
Trades by 5% holders
From the 60-day trade tables in 5% reports| Holder | Period | Net shares | Net % of shares | Avg. filed price | Range |
|---|---|---|---|---|---|
| individual filer | 2025-09-29 – 2026-10-30 | +7,094,949 | +27.18pt | ¥259.81 | ¥239–430 |
| individual filer | 2025-11-27 – 2026-10-14 | +2,219,500 | +10.10pt | ¥408.78 | ¥361–450 |
| Athos Capital Limited | 2024-10-10 – 2026-04-13 | +96,000 | +0.52pt | ¥360 | ¥360–360 |
| individual filer | 2021-11-19 – 2023-08-01 | -1,426,300 | −8.58pt | ¥518.82 | ¥460–979 |
Net shares and the average are our calculations. Prices are filed prices as stated by the filer, mostly for off-market trades; they are not market prices. Stock lending, custody transfers and option exercises are excluded from net shares. Every row via /v1/companies/4572/trades.
5% filings
Large shareholding reports on 4572| Filed | Filer | Stake | Change | Stated purpose |
|---|---|---|---|---|
| 2026-11-06 | individual filer | 24.57% | −1.08pt | pure investment |
| 2026-10-20 | individual filer | 13.68% | +7.02pt | pure investment |
| 2026-10-19 | individual filer | 25.65% | −1.59pt | pure investment |
| 2026-10-14 | individual filer | 6.66% | +1.52pt | pure investment |
| 2026-10-09 | individual filer | 27.24% | −1.10pt | pure investment |
| 2026-07-29 | individual filer | 28.34% | −1.87pt | pure investment |
| 2026-06-02 | individual filer | 30.21% | −1.29pt | pure investment |
| 2026-05-20 | individual filer | 31.50% | −1.70pt | pure investment |
| 2026-05-20 | individual filer | 33.20% | −1.70pt | pure investment |
| 2026-05-20 | individual filer | 34.90% | +19.88pt | pure investment |
Cross-shareholdings
From the annual report's status of shareholdings- Listed strategic holdings
- 1 issues
- Book value
- ¥17m
- Sold in the year
- — — issues
- Bought in the year
- ¥17m 1 issues
- Mutual, both reports
- 0
- Held by listed cos.
- 0
| Holds | Book value | Shares vs. prior year | Mutual |
|---|---|---|---|
| TOYO SECURITIES CO., LTD. 8614 | ¥17m | — | no |
Purposes, all holdings and mutual flags via /v1/companies/4572/cross-holdings. Share changes include stock splits.
Major shareholders
As of fiscal year end 2025-12-31| Shareholder | Shares | Ratio |
|---|---|---|
| MSIP CLIENT SECURITIES | 955,612 | 4.99% |
| individual holder | 555,500 | 2.90% |
| 小野薬品工業株式会社 | 504,500 | 2.63% |
| individual holder | 500,000 | 2.61% |
| individual holder | 468,800 | 2.44% |
| individual holder | 333,900 | 1.74% |
| individual holder | 255,000 | 1.33% |
| BNY GCM CLIENT ACCOUNT JPRD AC ISG （FE－AC） | 195,241 | 1.02% |
| BNYM SA／NV FOR BNYM FOR BNYM GCM CLIENT ACCTS M ILM FE | 180,304 | 0.94% |
| individual holder | 149,000 | 0.77% |
Get this as JSON
GET /v1/companies/4572
GET /v1/companies/4572/financials
GET /v1/companies/4572/details
GET /v1/companies/4572/segments
GET /v1/companies/4572/voting
GET /v1/companies/4572/tender-offers
GET /v1/companies/4572/indicators
GET /v1/companies/4572/earnings-releases
GET /v1/events?ticker=4572
GET /v1/companies/4572/trades
GET /v1/companies/4572/cross-holdings
GET /v1/companies/4572/brief